Pacific Bio (PACB) Reports In-Line Q4 EPS

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $36.96 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight